The encouraging in vitro and in vivo results of OC anti-TNBC activity via targeting the critical receptor tyrosine kinase (RTK) c-Met warranted further in vivo studies in more advanced heterogeneous tumor models [20,35,36,37]. This evidence concerns the gene MET and neoplasm.